European urology最新文献

{"title":"Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy—A New Standard for Guidelines on Prostate Cancer Detection?","authors":"John W. Davis","doi":"10.1016/j.eururo.2024.11.018","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.018","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"40 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies","authors":"Omar El-Taji, Noel W. Clarke","doi":"10.1016/j.eururo.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.005","url":null,"abstract":"High-risk, potentially lethal prostate cancer (PCa) requires systemic androgen deprivation therapy (ADT), with doublet therapy offering superior anticancer effects in comparison to monotherapy, and triplet therapy being more effective than doublet. However, nothing comes without a cost. In the review of such combination therapies by Aziz et al <span><span>[1]</span></span> in this issue of <em>European Urology</em>, the authors endeavour to add granularity to the existing evidence, showing that a significant cost on the final bill is a higher risk of cardiovascular toxicity. It is well established that cardiovascular disease (CVD) is a leading cause of death among PCa patients <span><span>[2]</span></span>, and men with pre-existing CVD fare worse: 18% of patients with baseline CVD in the HERO trial experienced a major adverse cardiac event within 1 yr of starting leuprolide <span><span>[3]</span></span>. The RADICAL-PC study demonstrated that in the real world, 99% of men harbour at least one, and 51% more than two, poorly controlled cardiovascular (CV) risk factors <span><span>[4]</span></span>. Should we be doing more to address this issue? Aziz et al <span><span>[1]</span></span> add weight to the evidence that we should, but there are caveats in interpretation of the data presented.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"16 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2024.11.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.020","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"233 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update","authors":"Elizabeth J. Schafer, Mathieu Laversanne, Hyuna Sung, Isabelle Soerjomataram, Alberto Briganti, William Dahut, Freddie Bray, Ahmedin Jemal","doi":"10.1016/j.eururo.2024.11.013","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.013","url":null,"abstract":"<h3>Background and objective</h3>Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.<h3>Methods</h3>We analyzed age-standardized PC incidence and mortality rates by country and region from the 2022 GLOBOCAN estimates and temporal trends in incidence (50 countries/territories) and mortality (59 countries/territories) rates using data from the <em>Cancer Incidence in Five Continents</em> series and the World Health Organization mortality database.<h3>Key findings and limitations</h3>Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.5-fold for mortality. The highest incidence rates were in Australia/New Zealand, North America, Northern Europe, and Latin America/Caribbean. The highest mortality rates were in sub-Saharan Africa and Latin America/Caribbean. During the most recent 5-yr period, incidence rates increased in 11 of the 50 countries included in the study and mortality rates increased in nine of 59 countries, mostly located in Africa, Asia, Latin America/Caribbean, and Central and Eastern Europe. Mortality rates decreased in 38 countries, largely located in Europe, Oceania, and Latin America/Caribbean. Limitations include the lack of data for low- and middle-income countries.<h3>Conclusions and clinical implications</h3>The increase in PC incidence and mortality rates in many countries in Africa, Asia, and Latin America/Caribbean may be because of increases in detection (incidence) and limited access to and availability of treatments (mortality only). The findings reinforce the importance of improving the health care infrastructure in these countries to mitigate the rising burden of PC.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"21 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.009","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"2 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.010","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"39 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgement to Reviewers","authors":"","doi":"10.1016/j.eururo.2024.10.027","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.027","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"82 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewer of the Year 2024","authors":"","doi":"10.1016/j.eururo.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.014","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"70 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers","authors":"Pedro C. Barata, Kevin K. Zarrabi, Axel Bex, Petros Grivas, Ken Hermann, Michael S. Hofman, Roger Li, Antonio Lopez-Beltran, Anwar R. Padani, Thomas Powles, Mary-Ellen Taplin, Yohann Loriot","doi":"10.1016/j.eururo.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.011","url":null,"abstract":"<h3>Background and objective</h3>Advances in molecular diagnostics have ushered in a new era for patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular modalities for the assessment of disease burden and minimal residual disease (MRD). Conventional imaging has a limited threshold for disease detection and is often unable to discern clinically occult disease with varying risks of false-negative or false-positive findings depending on the disease state and type of imaging.<h3>Methods</h3>We provide an overview of emerging radiographic and molecular tools in development within the genitourinary (GU) disease space. A literature review of contemporary basic, translational, and clinical research studies was performed, covering the timeframe of 1980–2024 through the MEDLINE (via PubMed) and Scopus databases. We highlight select examples of emerging technologies and biomarker-informed clinical trials, which aim to quantify disease at lower thresholds and have the potential for integrating MRD in clinical practice for GU patients.<h3>Key findings and limitations</h3>The development of novel radiotracers, such as prostate-specific membrane antigen or carbonic anhydrase IX, is being evaluated in both clinical practice and trial setting, aiming to change the management of these tumors. Molecular tools including circulating tumor cells and byproducts such as plasma and urine cell-free circulating tumor DNA provide the opportunity for MRD detection. MRD capture on single-cell or cellular byproducts can serve as a conduit for genomic and transcriptomic analyses, providing insight into the molecular underpinnings and clonal evolution of disease.<h3>Conclusions and clinical implications</h3>While the full potential for MRD applications has yet to be realized, we are witnessing the emergence of novel techniques aimed at MRD detection and the rapid development of elegantly designed studies implementing iterative detection of MRD as means to provide biological rationale and tailor therapeutic options in GU tumors.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"19 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial","authors":"Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, Bob-Valéry Occéan, Nadine Houédé, Arnauld Villers, Pascal Rischmann","doi":"10.1016/j.eururo.2024.11.006","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.006","url":null,"abstract":"<h3>Background and objective</h3>High-intensity focused ultrasound (HIFU) has emerged as an interesting ablative alternative to radical prostatectomy (RP) and radiation therapy (RT) for localized prostate cancer (PC). However, no prospective comparative data have been published for HIFU.<h3>Methods</h3>We performed a prospective nonrandomized nationwide trial in 46 centers in France comparing RP versus HIFU. The main inclusion criterion was low- to intermediate-risk PC. The primary endpoint was salvage therapy–free survival (STFS). Secondary endpoints were metastasis-free survival, PC-specific survival, overall survival, and functional outcomes.<h3>Key findings and limitations</h3>From 2015 to 2019, 3328 patients were included (1967 HIFU and 1361 RP). Median age was 74.7 versus 65.1 yr (<em>p</em> &lt; 0.001) and median PSA was 7.1 versus 6.9 ng/ml (<em>p</em> = 0.5) in the HIFU and RP groups, respectively. Intermediate-risk PC was diagnosed in 61% of patients in the HIFU group and 64% in the RP group (<em>p</em> = 0.10). The 30-mo STFS was not inferior in the HIFU group (hazard ratio 0.71, 95% confidence interval 0.52–0.97; <em>p</em> = 0.008). Some 10% of patients experienced urinary retention after HIFU. Grade &gt;IIIa complications occurred in 54/1967 cases in the HIFU group and 29/1361 cases in the RP group (<em>p</em> = 0.3). In the HIFU group, fewer patients experienced a deterioration in 12-mo urinary continence (29% vs 44%) and the decrease in median International Index of Erectile Function-5 score was lower (difference −7 vs −13) in comparison to RP. Internal Prostate Symptom Scores and quality-of-life scores were comparable in the two groups. The main limitations are the lack of randomization and the age difference between the groups.<h3>Conclusions and clinical implications</h3>This large prospective trial demonstrates that whole-gland or subtotal HIFU provides comparable medium-term STFS outcomes to RP. Urinary continence and erectile function were less impaired after HIFU. These results should be interpreted with caution owing to the lack of randomization and the age difference between the groups. Future research should consider longer follow-up and evaluate focal treatments.This trial is registered on ClinicalTrials.gov as NCT04307056.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"29 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}